INMB Q2 2024 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$10M

Net Income

-$10M

EPS (Diluted)

$-0.50

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$52M

Total Liabilities

$15M

Stockholders' Equity

$37M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$46,000	-100.0%
Gross Profit	$0	$46,000	-100.0%
Operating Income	-$10M	-$6M	-53.9%
Net Income	-$10M	-$7M	-49.9%